Condition: Hematologic Disorders · Hemoglobinopathies · Immunodeficiencies · Sponsor: Masonic Cancer Center, University of Minnesota
This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), is designed to promote engraftment in patients who failed to achieve an acceptable level of donor-derived engraftment following a previous allogeneic HCT.
This description comes directly from the study's public registry record.
Troy Lund, M.D., Ph.D. · 612-625-2508 · mill4991@umn.edu
Paul Orchard, M.D. · 612-626-2313 · orcha001@umn.edu
Always discuss trial participation with your own doctor first.
| Masonic Cancer Center, University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01666080